GIM
CRNX icon

Glenmede Investment Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Glenmede Investment Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$605K Sell
14,522
-2,612
-15% -$83.5K ﹤0.01% 855
2025
Q2 		$493K Buy
+17,134
New +$529K ﹤0.01% 934

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Glenmede Investment Management's CRNX Position: Q3 2025 in Review

Glenmede Investment Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 15% in Q3 2025, selling an estimated $83.5K and leaving 14,522 shares worth $605K. The position accounts for ﹤0.01% of the portfolio, ranked #855.

Glenmede Investment Management first reported a position in CRNX in Q2 2025 and has held it in 2 quarters since. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

  • Glenmede Investment Management held 14,522 shares of Crinetics Pharmaceuticals worth $605K as of Q3 2025.
  • Glenmede Investment Management sold 2,612 Crinetics Pharmaceuticals shares in Q3 2025, an estimated $83.5K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #855 holding.
  • Glenmede Investment Management first reported a position in Crinetics Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.